Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents

• DOI: 10.1016/j.bmcl.2007.11.112
• Publication Date: 2007-12-05T09:48:38Z
• Authors: Marco Radi; Emmanuele Crespan; Giorgia Botta; Federico Falchi; Giovanni Maga; Fabrizio Manetti; Valentina Corradi; Manuela Mancini; Maria Alessandra ...; Silvia Schenone; Maurizio Botta
• Keywords: ABL; Chronic myelogenous leukemia; K562 cells

A series of substituted benzoylamino-2-[(4-benzyl)thio]-1,3,4-thiadiazoles has been discovered as potent Abl tyrosine kinase inhibitors. Molecular docking simulations on the Abl tyrosine kinase were conducted in order to rationalize the SAR of the synthesized inhibitors. The most active compound identified from the enzymatic screening (6a) showed interesting inhibitory activity on Imatinib-sensitive murine myeloid 3B clone and Bcr-Abl-independent Imatinib-resistant leukemia cells. Surprisingly, 6a was also proved to act as differentiating inducers in human promyelocytic leukemia cells (HL-60).